Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment Varun Sasidharan NairReem SalehEyad Elkord Review Open access 03 February 2021 Pages: 2103 - 2121
Correction to: Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment Varun Sasidharan NairReem SalehEyad Elkord Correction Open access 07 July 2021 Pages: 2123 - 2123
Loss of type I IFN responsiveness impairs natural killer cell antitumor activity in breast cancer Damien J. ZankerKatie L. OwenBelinda S. Parker Original Article 15 January 2021 Pages: 2125 - 2138
Therapeutic vaccination targeting CD40 and TLR3 controls melanoma growth through existing intratumoral CD8 T cells without new T cell infiltration Aaron D. StevensTimothy N. J. Bullock Original Article 16 January 2021 Pages: 2139 - 2150
Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials Marit M. MelssenKarlyn E. PollackCraig L. Slingluff Jr Original Article 16 January 2021 Pages: 2151 - 2164
Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations Qiaofei LiuRonghua ZhangQuan Liao Original Article 17 January 2021 Pages: 2165 - 2177
Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC Meghan J. O’MeliaMargaret P. ManspeakerSusan N. Thomas Original Article 18 January 2021 Pages: 2179 - 2195
Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology Sabrina HoaLinda LaaouadShahin Jamal Original Article 20 January 2021 Pages: 2197 - 2207
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors Kevin TyanJoanna BaginskaOsama E. Rahma Original Article 22 January 2021 Pages: 2209 - 2221
Immunotherapy response modeling by ex-vivo organ culture for lung cancer Iris KamerElizabeta Bab-DinitzJair Bar Original Article 23 January 2021 Pages: 2223 - 2234
LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway Xiaoming WangYan ZhangXiubo Lu Original Article 24 January 2021 Pages: 2235 - 2245
miR-34a induces immunosuppression in colorectal carcinoma through modulating a SIRT1/NF-κB/B7-H3/TNF-α axis Fanyi MengMan YangWeipeng Wang Original Article 25 January 2021 Pages: 2247 - 2259
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient Runbo ZhongYunbin ZhangHua Zhong Original Article 27 January 2021 Pages: 2261 - 2274
Support of BCP-ALL-cells by autologous bone marrow Th-cells involves induction of AID expression but not widespread AID off-target mutagenesis Sabrina TraxelJulia LehmannSimone Bürgler Original Article Open access 28 January 2021 Pages: 2275 - 2289
T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model Emma H. A. StahlieViola FrankeAlexander C. J. van Akkooi Original Article 28 January 2021 Pages: 2291 - 2300
A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment Marino NagataAkemi KosakaHiroya Kobayashi Original Article 28 January 2021 Pages: 2301 - 2312
The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer Long JiangJia HuangQingquan Luo Original Article 29 January 2021 Pages: 2313 - 2321
The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta-analysis Yafei YouChang JiangLiangping Xia Original Article 29 January 2021 Pages: 2323 - 2335
Correction to: The predictive value of body mass index on prognosis and adverse events of cancers treated with immunotherapy: a systematic review and meta‑analysis Yafei YouChang JiangLiangping Xia Correction 20 March 2021 Pages: 2337 - 2337
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis Yi-Fang TsaiChi-Cheng HuangLing-Ming Tseng Original Article 29 January 2021 Pages: 2339 - 2351
CD30+OX40+ Treg is associated with improved overall survival in colorectal cancer Jian Hang LamMichelle HongTong Seng Lim Original Article Open access 02 February 2021 Pages: 2353 - 2365
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer Yuan LiZuhua ChenJie He Original Article 03 February 2021 Pages: 2367 - 2378
CAR19/22 T cell therapy in adult refractory Burkitt’s lymphoma Xiaoxi ZhouTong GeJianfeng Zhou Research Report 18 January 2021 Pages: 2379 - 2384
Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection Gurhan SismanErol BarburSibel Erdamar Cetin Research Report 22 January 2021 Pages: 2385 - 2388
Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden Ramin Salehi-RadRui LiSteven M. Dubinett Research Report Open access 28 January 2021 Pages: 2389 - 2400
Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment Sarah A. O’BrienJessica OrfJackson G. Egen Research Report Open access 29 January 2021 Pages: 2401 - 2410
Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy Kim KramerMaria A. DonzelliMelissa S. Pessin Research Report Open access 03 February 2021 Pages: 2411 - 2414
Correction to: Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti‑B7H3 immunotherapy Kim KramerMaria A. DonzelliMelissa S. Pessin Correction Open access 30 April 2021 Pages: 2415 - 2415